DRUGS & THERAPY PERSPECTIVES is an esteemed journal published by SpringerNature, dedicated to advancing knowledge in the field of pharmacology and therapeutic studies. With an ISSN of 1172-0360 and an E-ISSN of 1179-1977, this journal has been providing valuable insights since its inception in 1993 and continues to publish until 2024. Ranked in the Q3 category for Pharmacology (medical) and positioned within the 25th percentile according to Scopus rankings, it serves as a vital resource for researchers, practitioners, and students alike. Although it is not an open-access journal, it offers a comprehensive platform for innovative research, clinical practices, and evolving therapeutic strategies, reflecting the critical developments in drug therapy landscape. With its strategic emphasis on bridging academic studies and clinical applications, DRUGS & THERAPY PERSPECTIVES remains essential for those committed to enhancing drug efficacy and patient outcomes in the ever-evolving medical field.

Drug Healthcare and Patient Safety is a premier Open Access journal, published by DOVE MEDICAL PRESS LTD since 2009, dedicated to advancing the understanding and practices surrounding medication safety and healthcare delivery. With its ISSN 1179-1365 and E-ISSN matching, this New Zealand-based journal not only fosters global discourse but also prioritizes the dissemination of research that intersects both health policy and pharmacology. Categorized as Q2 in Health Policy and Q3 in Pharmacology for the year 2023, it occupies a notable position within the academic community, as reflected by its Scopus rankings, which place it in the 66th and 45th percentiles of its respective categories. Drug Healthcare and Patient Safety aims to provide a platform for researchers, practitioners, and students to share innovative findings, promote safe medication practices, and explore the implications of health policy on patient outcomes. As an Open Access journal, it ensures that vital research is accessible to a wider audience, making significant contributions to the ongoing dialogue in the fields of healthcare and pharmacovigilance.

JOURNAL OF PHARMACY PRACTICE AND RESEARCH is a pivotal platform dedicated to advancing knowledge and practice in the fields of pharmacy and pharmacology. Published by WILEY, this journal boasts a commendable impact factor, reflecting its contribution to the scientific community. With an ISSN of 1445-937X and E-ISSN 2055-2335, it emphasizes high-quality, peer-reviewed research essential for pharmacists, healthcare professionals, and researchers. Operating without an open-access model, it currently holds a Q3 ranking in Pharmacology and a Q2 ranking in Pharmacy according to the 2023 category quartiles, positioning it as a key resource for evidence-based practices and recent innovations in the pharmaceutical sciences. The journal spans from 2002 to 2024 and is recognized for enhancing the dialogue between academia and clinical practice. It provides a vital portal for exploring contemporary research trends and addressing pressing challenges in pharmacy practice, making it an indispensable resource for advancing professional development and improving patient care.

Integrated Pharmacy Research and Practice is a peer-reviewed, open-access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of pharmacy through innovative research and practice. With its ISSN 2230-5254, the journal has been providing a vital platform for disseminating new findings and best practices since its inception in 2012. Targeting researchers, practitioners, and students alike, it encompasses a broad scope that includes clinical pharmacy, drug regulation, and the socio-economic impact of pharmacy practices. Positioned in New Zealand's vibrant academic landscape, the journal aims to foster collaboration and knowledge sharing among professionals while upholding rigorous standards of scientific integrity. By offering unrestricted access to its content, Integrated Pharmacy Research and Practice plays a crucial role in shaping the future of pharmaceutical sciences and enhancing patient care globally.

Journal of Pharmacology & Pharmacotherapeutics is a vital academic resource published by SAGE Publications Inc., focusing on the diverse and evolving fields of pharmacology and pharmacotherapy. With an ISSN of 0976-500X and E-ISSN 0976-5018, this journal serves as a platform for rigorous research and innovative insights from 2010 to 2024, reflecting the latest advancements and challenges within the pharmacological landscape. Despite being placed in the Q4 quartile for both general pharmacology and medical pharmacology in 2023, it continues to be an essential resource for researchers, professionals, and students striving to understand the complexities of drug action, therapy optimization, and pharmaceutical sciences. The journal underscores the importance of disseminating critical findings to stimulate further research and collaborative dialogue. Although currently not open access, it can be accessed through leading academic databases, positioning itself as a significant entity in the medical and pharmacological research community.

JOURNAL OF PHARMACY PRACTICE, published by SAGE PUBLICATIONS INC, is a vital resource for researchers, pharmacy practitioners, and students dedicated to advancing the pharmacological and pharmaceutical sciences. Established in 1988, the journal serves as a platform for original research, reviews, and critical analyses in the fields of pharmacy and pharmacology. With an impressive impact factor and a strong presence in the Q2 category in Pharmacy and Q3 in Pharmacology (medical) as of 2023, it reflects the journal's commitment to delivering high-quality scholarly content that addresses pressing issues in pharmacy practice and medication management. The journal is indexed in Scopus, ranking #154 out of 272 in the field of Medicine and Pharmacology, positioning it within the 43rd percentile. Although it currently does not offer open access options, it remains an essential publication for those seeking to stay updated on innovations and best practices in the pharmacy sector, making it an indispensable tool for academic and professional growth.

Journal of Comparative Effectiveness Research is a leading academic journal dedicated to the evaluation of healthcare interventions and practices, published by Becaris Publishing. Since transitioning to a fully Open Access model in 2023, the journal has expanded its accessibility to a global audience of researchers, healthcare professionals, and policy makers. With a focus on comparative effectiveness in health policy, it has achieved a notable ranking of #132 out of 310 in the Scopus category for Medicine and Health Policy, placing it in the 57th percentile for scholarly impact. Operating from the United Kingdom, the journal encompasses research from 2012 to 2024 and firmly establishes itself in the academic landscape as a Q2 journal in the Health Policy category as of 2023. By disseminating high-quality, evidence-based research, the Journal of Comparative Effectiveness Research plays a vital role in informing clinical practice and health policy decision-making, making it an essential resource for those dedicated to improving health outcomes.

American Health and Drug Benefits, published by ENGAGE HEALTHCARE COMMUNICATIONS INC, is a pivotal journal dedicated to advancing the understanding of health policy and management in the pharmaceutical sector. Launched in 2009, this journal serves as a vital resource for researchers, practitioners, and policymakers engaged in the dynamic interplay between health care quality, drug accessibility, and effective management strategies. With its ISSN 1942-2962 and E-ISSN 1942-2970, the journal has established itself within the community, evidenced by its 2023 Scopus rankings, including Q4 in Health Policy and Q3 in Strategy and Management. Although currently lacking an open-access model, American Health and Drug Benefits remains a crucial platform for disseminating high-quality research that informs health care delivery and policy decisions in the United States. Its commitment to rigorous scholarship contributes to better health outcomes and fosters innovation in drug benefits management.

Ars Pharmaceutica is a distinguished open-access journal published by UNIV GRANADA, EDITORIAL, that has been at the forefront of pharmaceutical sciences since its establishment. With ISSN 0004-2927 and E-ISSN 2340-9894, this journal aims to disseminate high-quality research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of the field. With a historical scope that spans from 1980 to 2017, it has played a pivotal role in shaping the discourse surrounding pharmaceutical science and its intersection with the arts and humanities. Although currently ranked within the 13th percentile in Scopus for Pharmaceutical Science and the 11th percentile for History and Philosophy of Science, Ars Pharmaceutica continues to uphold its commitment to academic excellence and innovation. By providing a platform for open-access research, it encourages collaboration and knowledge sharing among researchers, professionals, and students, thus enhancing the broader understanding of pharmaceutical developments and their societal implications.

Therapeutic Advances in Drug Safety is a prestigious open-access journal published by SAGE Publications Ltd that has made significant strides in the field of pharmacology since its inception in 2010. With an impressive impact factor that places it in the Q1 category for Pharmacology (medical), this journal ranks 61st out of 272 in Scopus, showcasing its global influence and commitment to advancing drug safety research. Based in the United Kingdom, it aims to bridge the critical gap between pharmacological innovation and clinical application, offering a platform for the dissemination of groundbreaking research, case studies, and expert reviews. Since adopting an Open Access model in 2019, the journal has significantly increased its reach, ensuring that vital findings in drug safety are accessible to researchers, healthcare professionals, and educators worldwide. As the field of drug safety continues to evolve, Therapeutic Advances in Drug Safety remains an essential resource for those dedicated to enhancing safe therapeutic practices and patient outcomes.